Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Funt

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
European Urology|February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
European Urology|February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
Pageof 8